Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 4/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14767138 | 0.90 | MAPT (0.48) | MAPTFFAR1FFAR4PPARDTP53 | |
| SCHEMBL12823722 | 0.89 | MAPT (0.40) | PTGS2MAPTFFAR1FFAR4PPARD | |
| SCHEMBL12823728 | 0.88 | ADRB2 (0.38) | MAPTAPPCYP2C19 | |
| SCHEMBL12742782 | 0.88 | MAPT (0.45) | MAPTFFAR1FFAR4PPARDTP53 | |
| SCHEMBL13586234 | 0.88 | PTGS2 (0.40) | PTGS2MAPTFFAR1FFAR4PPARD | |
| SCHEMBL12742794 | 0.87 | MAPT (0.46) | MAPTFFAR1FFAR4PPARDTP53 | |
| SCHEMBL12822923 | 0.87 | MAPT (0.49) | MAPTFFAR1FFAR4PPARDTP53 | |
| SCHEMBL12742793 | 0.87 | MAPT (0.44) | MAPTFFAR1FFAR4PPARDTP53 | |
| SCHEMBL12823719 | 0.87 | CASR (0.36) | MAPTFFAR1FFAR4APPCYP2C19 | |
| SCHEMBL12742788 | 0.86 | MAPT (0.41) | MAPTFFAR1FFAR4PPARDTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | PTGS2 3919/4885MAPT 1075/4885FFAR1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.